Novo Nordisk, a global leader in the treatment of obesity and diabetes, signed a Memorandum of Understanding (MoU) with Al Ain Pharmacy Group, aimed at increasing awareness for obesity as a chronic disease, while engaging the public and healthcare professionals in Al Ain. As part of the
